Adding Arzerra to treatment with Treanda has failed to significantly extend progression-free survival in patients with indolent B cell non-Hodgkin’s lymphoma.
US regulators have expanded the approved uses of Novartis/Genmab’s Arzerra so that the biologic can now be used alongside fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukaemia.